CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 232 participants.
Also called NCT07612774
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 232 participants
- Sponsor
- Registry
-
NCT07612774
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07612774. Randomized; triple masking; primary purpose treatment. Start 2025-11-19 (actual); primary completion 2028-10-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS
- Acronym
- CAPRA-EVO
- Condition
- Coronary
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- Evolocumab
- Intervention (Diagnostic test)
- Serial photon-counting coronary computed tomography angiography
- Intervention (Drug)
- Standard Lipid-Lowering Therapy
- Lead sponsor
- West China Hospital
Record details
- Record id
cardio:ct-nct07612774- Content hash
9512b49e3d248c2b1b9f45c74892ca957ac2b0d1e2d2371d03cc39c5b0c714ea